top of page

Contract Human Cell Manufacturing


CET was the first company to introduce commercial human somatic stem cells to the research market in collaboration with Thermo Scientific.  CET has the largest portfolio of commercial human somatic stem cells and induced pluripotent stem cells (iPSC) for the research market.


Human Somatic Stem Cells


CET is a leading supplier of a variety of human somatic stem cells that include hematopoietic stem cells, mesenchymal stem cells, placenta epithelial stem cells and cord blood-derived multipotent stem cells.


First-in-kind, virus-free, integration-free, feeder-free and oncogene-free iPSC


CET has raised the bar in iPSC reprogramming by offering customers the first virus-free and oncogene-free iPSC reprogramming technology.  The use of viruses and current oncogenes (c-Myc and Lin28) can introduce disruptive viral and oncogenic alterations that could distort the native biology of iPSC models in drug discovery and certainly in cell therapy.  CET has developed a robust reprogramming technology using an episomal expression system that includes a combinatorial system of episomal vectors and a specialized reprogramming tissue culture media.  The system is very robust and has several advantages over current iPSC reprogramming technologies.


This media is xeno-free and converts targets cells into pluripotent colonies faster and more efficiently than any other media on the market. CET's iPSC reprogramming media works equally well with adherent cells and circulating mononuclear cells in which the latter have been pretreated with CET's hematopoietic stem cell differentiation media. Our media fully reprograms all colonies regardless of whether oncogenes (c-Myc and Lin28) are deleted from the reprogramming scheme.  This media will substantially reduce the cost and time of iPSC reprogramming and provide the most native diseased-specific and patient-specific iPSC models.  This technology has been validated in a recent peer-reviewed publication.


Full Service Patient and Disease-Specific iPSC Model Production


CET can provide a full range of services for clients to produce patient and disease-specific iPSC cell models.  These services include: patient recruitment, IRB support, tissue procurement and virus-free and oncogene-free iPSC reprogramming to create stocks of master cell lines.  We removed the burden to the customer by serving as a one-stop shop in the cell model development process.

bottom of page